• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Optimized Workflo

  2026-05-18

  Digoxin’s dual capability as a Na+/K+ ATPase pump inhibitor enables robust translational research workflows across cardiovascular and antiviral domains. This guide details stepwise protocols, cell-type nuances, and troubleshooting insights, maximizing experimental fidelity with APExBIO’s high-purity Digoxin.

• Sulfaphenazole: Innovating CYP2C9 Inhibition for Translation

  2026-05-18

  This thought-leadership article explores Sulfaphenazole as both a selective CYP2C9 inhibitor and a strategic tool for translational researchers. By integrating mechanistic insight, recent optimization strategies, and evidence-based protocol guidance, we reveal how Sulfaphenazole bridges vascular, metabolic, and infectious disease research. The piece differentiates itself by critically appraising the cross-domain applications and future directions for CYP2C9-targeted research.

• MK-1775 (Wee1 Kinase Inhibitor): Optimizing Assay Choice and

  2026-05-17

  Explore the advanced application of MK-1775, a potent Wee1 kinase inhibitor, with a deep dive into assay selection and nuanced data interpretation for p53-deficient cancer models. This article uniquely integrates recent methodological innovations to bridge mechanistic insight and experimental design.

• CRISPR/Cas9 Reversal of ABCB1-Mediated Tumor Drug Resistance

  2026-05-16

  This study demonstrates that CRISPR/Cas9-mediated knockout of the ABCB1 gene restores sensitivity to chemotherapeutic agents in multidrug-resistant (MDR) cancer cell lines. The findings provide a mechanistic framework for leveraging genome editing to overcome one of the major challenges in cancer therapy.

• T-5224 (C-Fos/AP-1 Inhibitor): Precision Tools for Inflammat

  2026-05-15

  T-5224, a selective C-Fos/AP-1 inhibitor from APExBIO, enables precise modulation of inflammatory and osteoclastogenic pathways in complex in vitro and in vivo models. This article delivers stepwise workflow guidance, actionable troubleshooting, and key translational insights for researchers targeting AP-1 driven processes in arthritis and neuroinflammation.

• DiR (DiIC 18 (7)) Unlocks Robust EV Tracking & MPS Evasion

  2026-05-15

  DiR (DiIC 18 (7)) empowers long-term, high-sensitivity membrane labeling in extracellular vesicle (EV) research, enabling precise tracking and optimizing 'Engage & Evasion' strategies against mononuclear phagocyte system (MPS) clearance. This guide translates cutting-edge workflow enhancements and troubleshooting tips into actionable protocols for advanced regenerative and cell migration studies.

• Chronic ONX-0914 Modulates Synaptic Plasticity and Gene Expr

  2026-05-14

  This study investigates how chronic administration of the selective immunoproteasome inhibitor ONX-0914 (PR-957) influences long-term potentiation (LTP) and glutamatergic signaling gene expression in the murine hippocampus. The findings reveal that non-constitutive proteasomes have a specific and nuanced role in synaptic plasticity, with implications for neuroimmune interactions and memory research.

• Dissecting Drug Response: Growth Inhibition vs Cell Death in

  2026-05-14

  Schwartz's dissertation provides a critical framework for distinguishing between growth inhibition and cell death in in vitro cancer drug response assays, highlighting the importance of fractional and relative viability metrics. This approach enables more nuanced evaluation of apoptosis inhibitors, such as survivin-targeted agents, improving translational relevance for preclinical cancer research.

• HotStart Universal 2X FAST Green qPCR Master Mix: Enhancing

  2026-05-13

  Discover how HotStart Universal 2X FAST Green qPCR Master Mix empowers advanced gene expression analysis in biofilm and antibiotic resistance studies. This article uniquely explores its application in dissecting Listeria monocytogenes virulence and biofilm mechanisms.

• 740 Y-P: Strategic Activation of PI3K in Translational Resea

  2026-05-13

  Explore how 740 Y-P, a potent PI 3-kinase activator from APExBIO, empowers translational researchers to dissect and modulate PI3K/AKT signaling in complex models of oxidative stress, vesicular trafficking, and neuronal survival. This article goes beyond protocol replication, providing mechanistic insights, evidence-driven recommendations, and strategic guidance for unlocking new frontiers in cancer and regenerative medicine.

• Protein A/G Magnetic Beads: Scenario-Driven Solutions in Cel

  2026-05-12

  This article delivers practical, scenario-based guidance for leveraging Protein A/G Magnetic Beads (SKU K1305) in cell viability, proliferation, and cytotoxicity workflows. Drawing on real-world laboratory challenges, it highlights how recombinant Protein A and Protein G beads from APExBIO support reproducibility, specificity, and efficient protein-protein interaction analysis.

• Palomid 529: Applied PI3K/Akt/mTOR Inhibition in Cancer Rese

  2026-05-12

  Palomid 529 (P529) offers dual mTORC1/2 inhibition and precise modulation of tumor angiogenesis, empowering researchers to model therapy resistance and metastatic processes in cancer. This guide delivers stepwise assay workflows, troubleshooting strategies, and evidence-driven applications, with actionable insights drawn from recent breakthroughs in PI3K/Akt pathway research.

• 5-Aminolevulinic acid HCl: Mechanistic Insight and Emerging

  2026-05-11

  Explore the multifaceted role of 5-Aminolevulinic acid HCl as a heme biosynthesis intermediate, with a focus on its mechanistic impact on pathogen immune evasion and advanced biomedical applications. Gain unique, evidence-based guidance for optimizing research protocols.

• Fasudil (HA-1077) HCl: Advanced ROCK Inhibition in Cell Fate

  2026-05-11

  Explore how Fasudil (HA-1077) HCl, a potent ROCK inhibitor, uniquely enables precise control over cell proliferation, migration, and apoptosis. This article delivers an in-depth analysis of its mechanistic selectivity and its pivotal role in dissecting ROCK-dependent pathways in cancer and hematological models.

• Icatibant as a KKS Modulator in Severe Viral Infections: Ins

  2026-05-10

  Mustonen et al. (2023) report on the use of icatibant, a bradykinin B2 receptor antagonist, in severe cases of nephropathia epidemica caused by Puumala hantavirus and discuss its potential in COVID-19 management. The study highlights the relevance of kinin-kallikrein system activation in viral pathogenesis and sets the stage for translational research bridging inflammatory and antiviral intervention strategies.

510 records 15/34 page Previous Next First page 上5页 1112131415 下5页 Last page